Table 1 |
|||||
| Expression of IMP3 in patients with lung adenocarcinoma | |||||
| Variable | N | IMP3 (Nā=ā90) | P | ||
| Negative N (%) | Positive N (%) | ||||
| Gradus | 1 | 18 | 8 (29.6) | 10 (15) | 0.287 |
| 2 | 23 | 7 (25.9) | 16 (25) | ||
| 3 | 49 | 12 (44) | 37 (58) | ||
| Subtype | solid | 52 | 9 (33) | 43 (68) | 0.002 |
| others | 38 | 18 (66) | 20 (31) | ||
| Napsin A | negative/light | 60 | 12 (46) | 48 (77) | 0.004 |
| strong positive | 28 | 14 (53) | 14 (22) | ||
| TTF-1 | negative | 31 | 9 (33.3) | 22 (39.2) | 0.599 |
| positive | 52 | 18 (66.6) | 34 (60.7) | ||
| Pleural effusion | no | 29 | 6 (42.8) | 3 (76.6) | 0.063 |
| yes | 15 | 8 (16.6) | 7 (23.3) | ||
| T staging | 2 | 10 | 4 (33.3) | 6 (21.4) | 0.458 |
| 3 | 10 | 2 (16.6) | 8 (28.5) | ||
| 4 | 20 | 6 (50) | 14 (50) | ||
| N staging | 1 | 20 | 9 (64) | 11 (52.3) | 0.612 |
| 2 | 14 | 5 (35) | 9 (42.8) | ||
| 3 | 1 | 0 | 1 (4) | ||
| M staging | 0 | 31 | 10 (37) | 22 (34.9) | 0.033 |
| 1a | 14 | 8 (29.6) | 6 (9.5) | ||
| 1b | 45 | 9 (33.3) | 36 (55.5) | ||
Ļ2 test.
Beljan Perak et al. Diagnostic Pathology 2012 7:165 doi:10.1186/1746-1596-7-165
